RIGL Stock Overview
A biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rigel Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.95 |
| 52 Week High | US$1.77 |
| 52 Week Low | US$0.71 |
| Beta | 1.04 |
| 1 Month Change | -1.69% |
| 3 Month Change | -29.93% |
| 1 Year Change | -40.44% |
| 3 Year Change | -77.42% |
| 5 Year Change | -58.57% |
| Change since IPO | -98.51% |
Recent News & Updates
Recent updates
Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding
May 01
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Mar 08Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement
Mar 04Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report
Feb 23Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S
Jan 15Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 25% Discount?
Oct 25Rigel cutting 16% of workforce after declining to file sNDA for fostamatinib
Oct 10Rigel Pharma adds ~7% to reach over two month high
Aug 18Rigel rises 17% on strong Q2 result
Aug 03Rigel Pharmaceuticals: A Status Check
May 31Is Rigel Pharmaceuticals (NASDAQ:RIGL) A Risky Investment?
Apr 21Rigel Pharmaceuticals: Why The Stock Is On A Run
Mar 21What Does The Future Hold For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)? These Analysts Have Been Cutting Their Estimates
Mar 06Rigel PharmaceuticalsA Biopharma With A Free Shot On Goal In COVID-19, With A Pipeline As A Safety Net
Feb 01An Intrinsic Calculation For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Suggests It's 26% Undervalued
Jan 14Rigel Pharmaceuticals: New Omicron Variant Keeps Tavalisse Treatment Prospects Alive
Nov 30Is Rigel Pharmaceuticals (NASDAQ:RIGL) Using Debt In A Risky Way?
Nov 02Rigel Pharma: Positive Data Supports Use Of Tavalisse In COVID-19 As Variants Subterfuge Vaccines
Sep 06It's Unlikely That Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) CEO Will See A Huge Pay Rise This Year
May 12Shareholder Returns
| RIGL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.3% | 0.2% | 1.2% |
| 1Y | -40.4% | 7.4% | 20.5% |
Return vs Industry: RIGL underperformed the US Biotechs industry which returned 7.4% over the past year.
Return vs Market: RIGL underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| RIGL volatility | |
|---|---|
| RIGL Average Weekly Movement | 8.0% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: RIGL's share price has been volatile over the past 3 months.
Volatility Over Time: RIGL's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 147 | Raul Rodriguez | www.rigel.com |
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company.
Rigel Pharmaceuticals, Inc. Fundamentals Summary
| RIGL fundamental statistics | |
|---|---|
| Market cap | US$170.83m |
| Earnings (TTM) | -US$19.80m |
| Revenue (TTM) | US$119.25m |
1.4x
P/S Ratio-8.4x
P/E RatioIs RIGL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RIGL income statement (TTM) | |
|---|---|
| Revenue | US$119.25m |
| Cost of Revenue | US$28.62m |
| Gross Profit | US$90.63m |
| Other Expenses | US$110.43m |
| Earnings | -US$19.80m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 76.00% |
| Net Profit Margin | -16.61% |
| Debt/Equity Ratio | -317.9% |
How did RIGL perform over the long term?
See historical performance and comparison